Metabolic HealthResearch PaperOpen Access

New NPY2 Receptor Drug Boosts GLP-1 Weight Loss by 31% in Mice

Nisotirostide, a novel NPY2R agonist, synergizes with GLP-1 drugs to amplify weight loss and improve glucose control independently of fat reduction.

Sunday, October 4, 2026 0 views
Published in Mol Metab
A close-up of a subcutaneous injection pen alongside a blood glucose monitor and a measuring tape on a clinical white surface

Summary

Many people with type 2 diabetes still struggle with blood sugar and weight even on GLP-1 drugs like dulaglutide. Researchers at Eli Lilly built nisotirostide, a long-lasting version of PYY3-36, a gut hormone that curbs appetite by activating the NPY2 receptor. In obese mice, it cut body weight by up to 12% alone and up to 31% when paired with a GLP-1 drug. It also improved blood sugar and insulin sensitivity even at doses that did not change weight. In a first-in-human trial of 65 people, a single dose added up to 2.58 kg of weight loss on top of dulaglutide in people with type 2 diabetes, and its pharmacokinetics supported once-weekly dosing. Side effects were mostly mild-to-moderate nausea and vomiting. Larger, longer, repeated-dose trials are needed.

Detailed Summary

Even with GLP-1 receptor agonists and dual GIP/GLP-1 drugs, many people with type 2 diabetes (T2D) fail to reach or hold their HbA1c and weight goals. One complementary target is peptide YY (PYY). Its main circulating form, PYY3-36, is released from the same gut cells as GLP-1 and acts through the NPY2 receptor (NPY2R) to reduce appetite. Infusing it lowered food intake by up to 33% over 24 hours in humans, but its half-life is only about 15 minutes, so it was impractical as a drug until analogs were engineered.

Nisotirostide (LY3457263) is a 34-amino-acid PYY3-36 analog with about 80% sequence identity to the native peptide. An attached C18 fatty diacid binds albumin to extend its half-life for once-weekly injection. In cell assays it was as potent as or more potent than native PYY3-36 (GTPγS EC50 78.6 pM vs 478 pM) and bound NPY2R with a Ki of 11.0 pM. It was far more selective, with over 450-fold lower affinity at NPY1R, over 30-fold at NPY4R and over 20-fold at NPY5R.

In diet-induced obese mice treated daily for two weeks (n=6 per group), vehicle animals gained 3% body weight while a dulaglutide surrogate alone produced no change. Nisotirostide alone lowered weight by 1%, 3% and 12% at 1, 3 and 10 nmol/kg (p<0.05 for the top two doses). Combined with the GLP-1 surrogate, weight fell 18%, 26% and 31%. Bliss independence testing confirmed synergy. Most of the loss was fat rather than lean mass.

A key finding was that glucose control improved independent of weight. At 1 and 3 nmol/kg, fasting body weight did not significantly change, yet fasting glucose, insulin and HOMA-IR all improved (p<0.05). Diabetic db/db mice showed the same pattern, with fasting insulin and HOMA-IR improving at doses that left weight unchanged.

The Phase 1 trial (NCT04641312) was a randomized, double-blind, placebo-controlled, single-ascending-dose study at two German centers. Part A enrolled healthy adults (43 enrolled, 41 dosed, 40 completed) at 0.025 to 1 mg. Part B enrolled 24 adults with T2D (BMI 27 to 40, HbA1c 7.0 to 9.5%) after a roughly 6-week run-in on dulaglutide 1.5 mg weekly. Each cohort had 6 active and 2 placebo participants. Pharmacokinetics supported once-weekly dosing. At 1 mg as monotherapy, weight fell 0.75 kg versus placebo (not significant). Added to dulaglutide, nisotirostide reduced weight by up to 2.58 kg versus dulaglutide alone (p<0.05). Nausea and vomiting were the most common adverse events, dose-dependent and mild-to-moderate.

These data give early proof of concept for adding NPY2R agonism to GLP-1 therapy. Caveats are substantial. The trial used a single dose, measured weight over a short window, and was not powered for efficacy. Cohorts were small and the effect on glucose in humans needs confirmation in repeated-dose studies. The sponsor, Eli Lilly, helped design the study, analyze the data and draft the report.

Key Findings

  • Nisotirostide bound human NPY2R with a Ki of 11.0 pM and had >450-fold, >30-fold and >20-fold lower affinity at NPY1R, NPY4R and NPY5R, respectively
  • In diet-induced obese mice, nisotirostide alone cut body weight by 12% at 10 nmol/kg (p<0.05 vs vehicle, which gained 3%)
  • Combined with a dulaglutide surrogate, mice lost 18%, 26% and 31% of body weight at 1, 3 and 10 nmol/kg, with synergy confirmed by Bliss independence analysis
  • At 1 and 3 nmol/kg, fasting glucose, insulin and HOMA-IR improved (p<0.05) with no significant change in fasting body weight, suggesting weight-independent glycemic benefit
  • In the Phase 1 study (N=65), a 1 mg dose as monotherapy reduced weight by 0.75 kg vs placebo (not significant)
  • Added to 1.5 mg weekly dulaglutide in adults with T2D, nisotirostide reduced weight by up to 2.58 kg vs dulaglutide alone (p<0.05)
  • Nausea and vomiting were the most common adverse events, dose-dependent and mild-to-moderate, and PK supported once-weekly subcutaneous dosing

Methodology

Preclinical work used cell-based cAMP, GTPγS and radioligand binding assays, plus lean, db/db and diet-induced obese mouse studies (n=6 per group in the DIO study) analyzed with one-way ANOVA and Dunnett's test, with synergy tested by the Bliss Independence method. The clinical study was a randomized, double-blind, placebo-controlled, single-ascending-dose Phase 1 trial at two German centers: Part A in healthy adults (0.025 to 1 mg) and Part B in adults with T2D on dulaglutide 1.5 mg weekly (6 active and 2 placebo per cohort). The primary endpoint was safety and tolerability; secondary was PK; and body weight, OGTT and acetaminophen-based gastric emptying were exploratory. The sample size was not powered for pharmacodynamic inference.

Study Limitations

The human study was a small, single-dose Phase 1 trial not powered for efficacy, so weight and glucose findings are exploratory and short-term. Mouse data came from small groups (n=6), male DIO mice and short treatment durations, and the combination was not tested in the glucose endpoints. Eli Lilly funded the study and was involved in its design, data analysis and report drafting.

Enjoyed this summary?

Get the latest longevity research delivered to your inbox every week.

Enter your email to subscribe: